Brigitte I Frohnert1, Lisa Ide2, Fran Dong2, Anna E Barón3, Andrea K Steck2, Jill M Norris4, Marian J Rewers2. 1. Barbara Davis Center for Childhood Diabetes, School of Medicine, University of Colorado, 1775 Aurora Court, A140, Aurora, CO, 80045, USA. brigitte.frohnert@ucdenver.edu. 2. Barbara Davis Center for Childhood Diabetes, School of Medicine, University of Colorado, 1775 Aurora Court, A140, Aurora, CO, 80045, USA. 3. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado, Aurora, CO, USA. 4. Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, CO, USA.
Abstract
AIMS/HYPOTHESIS: We sought to assess the frequency, determinants and prognosis for future diabetes in individuals with islet autoimmunity and whether these factors differ depending on the age of onset of islet autoimmunity. METHODS: A prospective cohort (n = 2547) of children from the general population who had a high-risk HLA genotype and children who had a first-degree relative with type 1 diabetes were followed for up to 21 years. Those with the persistent presence of one or more islet autoantibodies were categorised as early-onset (<8 years of age, n = 143, median 3.3 years) or late-onset (≥8 years of age, n = 64, median 11.1 years), and were followed for a median of 7.4 and 4.7 years, respectively. Progression to diabetes was evaluated by Kaplan-Meier analysis with logrank test. Factors associated with progression to diabetes were analysed using the parametric accelerated failure time model. RESULTS: Children with late-onset islet autoimmunity were more likely to be Hispanic or African-American than non-Hispanic white (p = 0.004), and less likely to be siblings of individuals with type 1 diabetes (p = 0.04). The frequencies of the HLA-DR3/4 genotype and non-HLA gene variants associated with type 1 diabetes did not differ between the two groups. However, age and HLA-DR3/4 were important predictors of rate of progression to both the presence of additional autoantibodies and type 1 diabetes. Late-onset islet autoimmunity was more likely to present with a single islet autoantibody (p = 0.01) and revert to an antibody-negative state (p = 0.01). Progression to diabetes was significantly slower in children with late-onset islet autoimmunity (p < 0.001). CONCLUSIONS/ INTERPRETATION: A late onset of islet autoimmunity is more common in African-American and Hispanic individuals. About half of those with late-onset islet autoimmunity progress to show multiple islet autoantibodies and develop diabetes in adolescence or early adulthood. Further investigation of environmental determinants of late-onset autoimmunity may lead to an understanding of and ability to prevent adolescent and adult-onset type 1 diabetes.
AIMS/HYPOTHESIS: We sought to assess the frequency, determinants and prognosis for future diabetes in individuals with islet autoimmunity and whether these factors differ depending on the age of onset of islet autoimmunity. METHODS: A prospective cohort (n = 2547) of children from the general population who had a high-risk HLA genotype and children who had a first-degree relative with type 1 diabetes were followed for up to 21 years. Those with the persistent presence of one or more islet autoantibodies were categorised as early-onset (<8 years of age, n = 143, median 3.3 years) or late-onset (≥8 years of age, n = 64, median 11.1 years), and were followed for a median of 7.4 and 4.7 years, respectively. Progression to diabetes was evaluated by Kaplan-Meier analysis with logrank test. Factors associated with progression to diabetes were analysed using the parametric accelerated failure time model. RESULTS:Children with late-onset islet autoimmunity were more likely to be Hispanic or African-American than non-Hispanic white (p = 0.004), and less likely to be siblings of individuals with type 1 diabetes (p = 0.04). The frequencies of the HLA-DR3/4 genotype and non-HLA gene variants associated with type 1 diabetes did not differ between the two groups. However, age and HLA-DR3/4 were important predictors of rate of progression to both the presence of additional autoantibodies and type 1 diabetes. Late-onset islet autoimmunity was more likely to present with a single islet autoantibody (p = 0.01) and revert to an antibody-negative state (p = 0.01). Progression to diabetes was significantly slower in children with late-onset islet autoimmunity (p < 0.001). CONCLUSIONS/ INTERPRETATION: A late onset of islet autoimmunity is more common in African-American and Hispanic individuals. About half of those with late-onset islet autoimmunity progress to show multiple islet autoantibodies and develop diabetes in adolescence or early adulthood. Further investigation of environmental determinants of late-onset autoimmunity may lead to an understanding of and ability to prevent adolescent and adult-onset type 1 diabetes.
Entities:
Keywords:
Age of diabetes onset; Autoantibodies; Child; Ethnic differences; Islet autoantibody; Racial differences; Type 1 diabetes
Authors: Jeffrey P Krischer; Kristian F Lynch; Desmond A Schatz; Jorma Ilonen; Åke Lernmark; William A Hagopian; Marian J Rewers; Jin-Xiong She; Olli G Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Ezio Bonifacio Journal: Diabetologia Date: 2015-02-10 Impact factor: 10.122
Authors: V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell Journal: Diabetologia Date: 2012-03-23 Impact factor: 10.122
Authors: Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: Lars C Stene; Katherine Barriga; Michelle Hoffman; Jaime Kean; Georgeanna Klingensmith; Jill M Norris; Henry A Erlich; George S Eisenbarth; Marian Rewers Journal: Pediatr Diabetes Date: 2006-10 Impact factor: 4.866
Authors: S M Virtanen; M G Kenward; M Erkkola; S Kautiainen; C Kronberg-Kippilä; T Hakulinen; S Ahonen; L Uusitalo; S Niinistö; R Veijola; O Simell; J Ilonen; M Knip Journal: Diabetologia Date: 2006-04-05 Impact factor: 10.122
Authors: Andrea K Steck; Fran Dong; Randall Wong; Alexandra Fouts; Edwin Liu; Jihane Romanos; Cisca Wijmenga; Jill M Norris; Marian J Rewers Journal: Pediatr Diabetes Date: 2013-11-08 Impact factor: 4.866
Authors: Stephen R Karpen; Jessica L Dunne; Brigitte I Frohnert; Marjana Marinac; Claudia Richard; Sarah E David; Inish M O'Doherty Journal: Diabetologia Date: 2022-07-22 Impact factor: 10.460
Authors: Pia Leete; Roberto Mallone; Sarah J Richardson; Jay M Sosenko; Maria J Redondo; Carmella Evans-Molina Journal: Curr Diab Rep Date: 2018-09-26 Impact factor: 4.810
Authors: R Brett McQueen; Cristy Geno Rasmussen; Kathleen Waugh; Brigitte I Frohnert; Andrea K Steck; Liping Yu; Judith Baxter; Marian Rewers Journal: Diabetes Care Date: 2020-04-23 Impact factor: 19.112
Authors: Maria J Redondo; Susan Geyer; Andrea K Steck; Jay Sosenko; Mark Anderson; Peter Antinozzi; Aaron Michels; John Wentworth; Ping Xu; Alberto Pugliese Journal: Diabetes Care Date: 2017-10-12 Impact factor: 19.112
Authors: Maria J Redondo; Susan Geyer; Andrea K Steck; Seth Sharp; John M Wentworth; Michael N Weedon; Peter Antinozzi; Jay Sosenko; Mark Atkinson; Alberto Pugliese; Richard A Oram Journal: Diabetes Care Date: 2018-07-12 Impact factor: 19.112
Authors: Brigitte I Frohnert; Bobbie-Jo Webb-Robertson; Lisa M Bramer; Sara M Reehl; Kathy Waugh; Andrea K Steck; Jill M Norris; Marian Rewers Journal: Diabetes Date: 2019-11-18 Impact factor: 9.461
Authors: Suna Onengut-Gumuscu; Umadevi Paila; Wei-Min Chen; Aakrosh Ratan; Zhennan Zhu; Andrea K Steck; Brigitte I Frohnert; Kathleen C Waugh; Bobbie-Jo M Webb-Robertson; Jill M Norris; Leslie A Lange; Marian J Rewers; Stephen S Rich Journal: Sci Rep Date: 2020-11-05 Impact factor: 4.379
Authors: Bobbie-Jo M Webb-Robertson; Lisa M Bramer; Bryan A Stanfill; Sarah M Reehl; Ernesto S Nakayasu; Thomas O Metz; Brigitte I Frohnert; Jill M Norris; Randi K Johnson; Stephen S Rich; Marian J Rewers Journal: J Diabetes Date: 2020-08-16 Impact factor: 4.006